Stanford Univ Med Ctr. / Lucile Packard Children's Hosp

Palo Alto, CA

Sorting 3 by

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

ACCELERATE

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Post-Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2